Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Sep;10(3):405-413.
doi: 10.1007/s40801-023-00366-2. Epub 2023 Apr 27.

Post-Marketing Safety Study of Ramucirumab Plus FOLFIRI: Analysis of Age and Initial Dose of Irinotecan in Patients with Metastatic Colorectal Cancer

Toshiki Masuishi  1 , Soshi Nagaoka  2 , Long Jin  2 , Kenichi Yoshizawa  3
Affiliations

Post-Marketing Safety Study of Ramucirumab Plus FOLFIRI: Analysis of Age and Initial Dose of Irinotecan in Patients with Metastatic Colorectal Cancer

Toshiki Masuishi et al. Drugs Real World Outcomes. 2023 Sep.

Abstract

Background: There is limited real-world evidence regarding the safety of ramucirumab plus FOLFIRI in patients with metastatic colorectal cancer (mCRC).

Objective: We evaluated the safety of ramucirumab plus FOLFIRI in patients with mCRC by age and initial dose of irinotecan.

Patients and methods: This single-arm, prospective, multicenter, non-interventional, observational study was conducted between December 2016 and April 2020. Patients were observed for 12 months.

Results: Of 366 enrolled Japanese patients, 362 were eligible for study inclusion. The frequency of grade ≥ 3 adverse events (AEs) by age (≥ 75 years vs < 75 years) was 56.1% versus 50.2%, indicating no substantial differences between age groups. Grade ≥ 3 notable AEs, including neutropenia, proteinuria, and hypertension, were also similar in both age groups, but the frequency of any grade venous thromboembolic events was higher in those aged ≥ 75 years than in those aged < 75 years (7.0% vs 1.3%). The frequency of grade ≥ 3 AEs was slightly lower in patients receiving > 150 mg/m2 of irinotecan than in those receiving ≤ 150 mg/m2 of irinotecan (42.1% vs 53.6%); however, the frequency of grade ≥ 3 diarrhea, but not any grade diarrhea, and liver failure/injury was higher in patients receiving > 150 mg/m2 of irinotecan than in those receiving ≤ 150 mg/m2 of irinotecan (4.6% vs 1.9% and 9.1% vs 2.3%, respectively).

Conclusions: The safety profile of ramucirumab plus FOLFIRI in mCRC patients was similar in subgroups by age and initial irinotecan dose in real-world settings.

Plain language summary

Colorectal cancer (CRC), also known as bowel cancer, is a common cancer and a leading cause of death. Chemotherapy is a treatment option for CRC. It consists of one or more powerful medications to destroy cancer cells with the aim of prolonging life and reducing symptoms. These medications can cause side effects such as nausea, vomiting, infections, and high blood pressure. Sometimes these side effects can be so severe that patients stop or reduce their treatment. The safety and efficacy of these anti-cancer drugs are established from clinical trials, but, in daily clinical practice, patient outcomes are affected by various factors, such as general health, age, prior treatments, and lifestyle. Ramucirumab plus FOLFIRI is considered a standard treatment for CRC in patients who have disease progression after first-line treatment. In this study, we collected data from patients with CRC who were given ramucirumab plus FOLFIRI under routine clinical practice in Japan. Data were collected for 12 months from the start of treatment and based on various patient demographics such as age less than or greater than 75 years and treatment with a lower or higher dose of the anti-cancer drug irinotecan. We found that ramucirumab plus FOLFIRI is manageable in patients with CRC regardless of these patient demographics and initial irinotecan dose. This article aims to inform patients and primary care providers regarding real-world treatment outcomes to assist with CRC treatment decision making.

PubMed Disclaimer

Conflict of interest statement

Toshiki Masuishi has received personal fees from Takeda, Chugai, Merck Bio Pharma, Taiho, Bayer, Eli Lilly Japan K.K., Yakult Honsha, Ono, Bristol Myers Squibb, Daiichi Sankyo, and Sanofi, and grants from MSD, Daiichi Sankyo, Ono, and Novartis. Soshi Nagaoka is an employee of Eli Lilly Japan K.K. and a shareholder of Eli Lilly and Company. Long Jin is an employee of Eli Lilly Japan K.K. Kenichi Yoshizawa is an employee of Eli Lilly Japan K.K. and a shareholder of Eli Lilly and Company, Bristol-Myers Squibb Company, and Merck & Co., Inc.

Figures

Fig. 1
Fig. 1
Survival analysis generated using the Kaplan-Meier method by a patients aged < 75 and ≥ 75 years and b dose of initial irinotecan therapy. The number of deaths/censored are presented as n (%). Survival time is presented as point estimate (95% CI). a Censored at the last date when the survival status was confirmed. CI, confidence interval
See this image and copyright information in PMC

References

    1. Paulík A, Nekvindová J, Filip S. Irinotecan toxicity during treatment of metastatic colorectal cancer: focus on pharmacogenomics and personalized medicine. Tumori. 2020;106:87–94. doi: 10.1177/0300891618811283. - DOI - PubMed
    1. Van Cutsem E, Cervantes A, Adam R, Sobrero A, Van Krieken JH, Aderka D, et al. ESMO consensus guidelines for the management of patients with metastatic colorectal cancer. Ann Oncol. 2016;27:1386–1422. doi: 10.1093/annonc/mdw235. - DOI - PubMed
    1. Hashiguchi Y, Muro K, Saito Y, Ito Y, Ajioka Y, Hamaguchi T, et al., Japanese Society for Cancer of the Colon and Rectum. Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2019 for the treatment of colorectal cancer. Int J Clin Oncol. 2020;25:1–42. 10.1007/s10147-019-01485-z - PMC - PubMed
    1. Benson AB, Venook AP, Al-Hawary MM, Arain MA, Chen Y-J, Ciombor KK, et al. Colon Cancer, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Cancer Netw. 2021;19:329–59. https://jnccn.org/view/journals/jnccn/19/3/article-p329.xml?ArticleBodyC.... Accessed 20 Feb 2023. - PubMed
    1. Tabernero J, Yoshino T, Cohn AL, Obermannova R, Bodoky G, Garcia-Carbonero R, et al., RAISE Study Investigators. Ramucirumab versus placebo in combination with second-line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine (RAISE): a randomised, double-blind, multicentre, phase 3 study. Lancet Oncol. 2015;16:499–508. 10.1016/s1470-2045(15)70127-0. - PubMed

LinkOut - more resources